TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17229079

Group type: EXPERIMENTAL
Intervention: Daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low‐dose CsA (target trough levels of 50‐100 ng/mL), weaned from month 4 and withdrawn by month 6
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Daclizumab, MMF, CS and low‐dose CsA
Number of subjects: 536

Group type: COMPARATOR
Intervention: MMF, CS and standard‐dose CsA
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: CsA withdrawal group
Number of subjects: 536

Group type: COMPARATOR
Intervention: Low‐dose CsA group
Number of subjects: 536

Group type: COMPARATOR
Intervention: Standard‐dose CsA group
Number of subjects: 536
Study: 15820814

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus tibolone (group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus placebo tablets (group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Injection of a placebo solution plus placebo tablets (group C)
Number of subjects: 120
Study: 12212781

Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone daily for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9797627

Group type: EXPERIMENTAL
Intervention: Weaning regimen CPAP for 72 hours (n = 29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Rescue regimen CPAP (n = 29)
Number of subjects: 58
Study: 8564348

Group type: EXPERIMENTAL
Intervention: Disodium pamidronate 30 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Disodium pamidronate 45 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Disodium pamidronate 60 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Comparison of response rates in three therapeutic groups
Number of subjects: 38
Study: 2523525

Group type: EXPERIMENTAL
Intervention: 3 x 5 micrograms doses of Engerix B recombinant DNA hepatitis B vaccine
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 3 x 10 micrograms doses of Engerix B recombinant DNA hepatitis B vaccine
Number of subjects: 215
Study: 58198

Group type: EXPERIMENTAL
Intervention: Atropine plus droperidol
Number of subjects: 158

Group type: COMPARATOR
Intervention: Atropine plus diazepam
Number of subjects: 158

Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 158
Study: 31277138

Group type: EXPERIMENTAL
Intervention: Celecoxib combined with chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Celecoxib combined with chemotherapy (for COX-2 positive patients)
Number of subjects: 100
Study: 29276907

Group type: EXPERIMENTAL
Intervention: Bisoprolol (6.9±2.2 mg/day, n=25)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sotalol (162.5±46.2 mg/day, n=24)
Number of subjects: 49
Study: 25115995

Group type: EXPERIMENTAL
Intervention: 5% Sodium hypochlorite (NaOCl) used as a cleansing agent in pulpotomy procedures
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CH) as pulpotomy material
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) as pulpotomy material
Number of subjects: 128

Group type: COMPARATOR
Intervention: Physiologic saline used as a cleansing agent in pulpotomy procedures
Number of subjects: 128
Study: 24810309

Group type: EXPERIMENTAL
Intervention: Amniotic membrane (AM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Skin graft
Number of subjects: 30
Study: 23055504

Group type: EXPERIMENTAL
Intervention: Joint motion/disparity grating
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure disparity gratings
Number of subjects: 0
Study: 18514464

Group type: EXPERIMENTAL
Intervention: ATNAA auto-injector
Number of subjects: 56

Group type: COMPARATOR
Intervention: Mark I auto-injector
Number of subjects: 56

Group type: COMPARATOR
Intervention: Traditional needle/syringe
Number of subjects: 56
Study: 17466405

Group type: EXPERIMENTAL
Intervention: Video‐assisted mediastinoscopy (VAM)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Thoracotomy without VAM (Group A)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Thoracotomy with extended dissection of mediastinal lymph nodes (Group C)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Group A (stage IA patients)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Group B (stage IA patients)
Number of subjects: 359
Study: 15204273

Group type: EXPERIMENTAL
Intervention: E-mail alert occurring 1000 ms before collision warning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E-mail alert occurring 300 ms before collision warning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly urgent sounds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annoyance ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Differences in rated urgency of collision warnings and e-mail alerts
Number of subjects: 0
Study: 15963391

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 52
Study: 10516515

Group type: EXPERIMENTAL
Intervention: Ketanserin 0.5% eye drops
Number of subjects: 0
Study: 8969573

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-term placebo-controlled trials
Number of subjects: 0
Study: 1882896

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g granulate four times daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 60
Study: 6309542

Group type: EXPERIMENTAL
Intervention: Enprofylline (3.5 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Theophylline (9.5 mg/kg)
Number of subjects: 8
Study: 30634195

Group type: EXPERIMENTAL
Intervention: Low-volume bowel preparation (0.3L sodium picosulfate with magnesium citrate)
Number of subjects: 13497

Group type: COMPARATOR
Intervention: Standard-volume bowel preparation (4L polyethylene glycol)
Number of subjects: 13497
Study: 29274618

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (TAS-102)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 25731653

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (immediate clamping)
Number of subjects: 54
Study: 24330449

Group type: EXPERIMENTAL
Intervention: Bupivacaine TAP block (15 mL of 0.25% Bupivacaine plus 5 μ/ml epinephrine)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline TAP block (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Bupivacaine TAP block
Number of subjects: 44
Study: 22329791

Group type: EXPERIMENTAL
Intervention: Interference pairs (COTTON-PRINT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Novel pairs (HOST-VASE)
Number of subjects: 0
Study: 20489741

Group type: EXPERIMENTAL
Intervention: Red-light soft magnetic field laser stimulation of conception vessel 24 (CV 24) for 1 min
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of laser stimulation of CV 24 and acupressure pericardium 6 (PC 6)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo group (no active intervention)
Number of subjects: 45
Study: 18412759

Group type: EXPERIMENTAL
Intervention: Follicular phase (F)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Luteal phase (L)
Number of subjects: 202
Study: 15750042

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg twice daily for 4 weeks, then 50 mg three times daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bosentan (62.5 mg twice daily for 4 weeks, then 125 mg twice daily)
Number of subjects: 26
Study: 12390634

Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 61847
Study: 10499226

Group type: EXPERIMENTAL
Intervention: SCT‐based workshop
Number of subjects: 88

Group type: COMPARATOR
Intervention: Didactic workshop
Number of subjects: 88
Study: 8544280

Group type: EXPERIMENTAL
Intervention: Clonidine 4.0-5.5 micrograms.kg‐1 orally 90 minutes before surgery
Number of subjects: 16

Group type: COMPARATOR
Intervention: No premedication (Control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clonidine group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 1749871

Group type: EXPERIMENTAL
Intervention: 20 mg of isosorbide dinitrate sustained release (ISDN-SR) four times daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: 40 mg of isosorbide dinitrate sustained release (ISDN-SR) twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Comparison of 20 mg four times daily vs 40 mg twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both dosage regimens
Number of subjects: 11
Study: 30785379

Group type: EXPERIMENTAL
Intervention: Integrated Care for the Reduction of Secondary Stroke (ICARUSS) model
Number of subjects: 249

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 249
Study: 31167023

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 121

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 121

Group type: COMPARATOR
Intervention: Baseline MDD vs Healthy Controls
Number of subjects: 121
Study: 27927938

Group type: EXPERIMENTAL
Intervention: 1 mA cathodal tDCS over the contralesional primary motor cortex for 20 minutes during daily therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 24
Study: 26271200

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 0
Study: 24136267

Group type: EXPERIMENTAL
Intervention: Minimal invasive internal fixation with U-shaped break-off pedicle screws (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional posterior midline approach and open procedure (Group B)
Number of subjects: 40
Study: 21422768

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (E-EPA) 1 g/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19968409

Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 116

Group type: COMPARATOR
Intervention: No-alcohol control beverage
Number of subjects: 116
Study: 16897990

Group type: EXPERIMENTAL
Intervention: S-1 (80 mg/m2/day for 4 weeks followed by 2 weeks rest for a year)
Number of subjects: 800

Group type: COMPARATOR
Intervention: UFT (400 mg/m2/day for 5 days followed by 2 days rest for a year)
Number of subjects: 800
Study: 15163474

Group type: EXPERIMENTAL
Intervention: Mg + Zn (200 mg Mg and 30 mg Zn)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Vitamins C + E (200 mg Vitamin C and 150 mg Vitamin E)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combination of Mg + Zn and Vitamins C + E
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 11339401

Group type: EXPERIMENTAL
Intervention: Vapor-cut
Number of subjects: 100

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 100
Study: 9159306

Group type: EXPERIMENTAL
Intervention: Usual MAP goal of 102 to 107 mm Hg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker regimen (amlodipine)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Beta-blocker regimen (atenolol)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ACE inhibitor regimen (enalapril)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Low MAP goal of < or = 92 mm Hg
Number of subjects: 94
Study: 7965632

Group type: EXPERIMENTAL
Intervention: Microsphere assay
Number of subjects: 69

Group type: COMPARATOR
Intervention: Flow cytometry
Number of subjects: 69

Group type: COMPARATOR
Intervention: Immunofluorescence microscopy
Number of subjects: 69
Study: 3309430

Group type: EXPERIMENTAL
Intervention: Propranolol during 30-60 W exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol during 90 W exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control bicycle-ergometric test
Number of subjects: 16
Study: 31711513

Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived stromal cells (ASCs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study: 27702823

Group type: COMPARATOR
Intervention: Cabazitaxel 25 mg/m2 every 3 weeks plus prednisone 10 mg/day (group CABA)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m2 every 3 weeks with concomitant budesonide 9 mg daily during the first two treatment cycles (group BUD)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Both groups (CABA and BUD)
Number of subjects: 246
Study: 26222846

Group type: EXPERIMENTAL
Intervention: Mild caloric restriction during a 3 to 6-day hospitalization
Number of subjects: 10
Study: 23802920

Group type: EXPERIMENTAL
Intervention: Reduced-volume sprint interval training (SIT) - 6 sessions of 8-12 x 10s sprints
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional exercise recommendations (TER) - 10 sessions of 30 min at 65% peak oxygen consumption (VO(2peak))
Number of subjects: 16
Study: 21783046

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 54
Study: 19539073

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents in diabetic patients
Number of subjects: 7492

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents in nondiabetic patients
Number of subjects: 7492
Study: 16306998

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/HCTZ 12.5 mg o.d.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Lisinopril 20 mg/HCTZ 12.5 mg o.d.
Number of subjects: 160
Study: 14551698

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0
Study: 11055772

Group type: EXPERIMENTAL
Intervention: Betula 30c tablets
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 66
Study: 9463204

Group type: EXPERIMENTAL
Intervention: Perioperative corticoid treatment (CC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No perioperative corticoid treatment (NCC)
Number of subjects: 46
Study: 8382291

Group type: EXPERIMENTAL
Intervention: Biodegradable implants
Number of subjects: 43

Group type: COMPARATOR
Intervention: Steel implants
Number of subjects: 43
Study: 3486551

Group type: EXPERIMENTAL
Intervention: Nurse-run outpatient hypertension clinics
Number of subjects: 2806

Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 2806
Study: 31605641

Group type: EXPERIMENTAL
Intervention: Extensive intervention (education + professional cleaning)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Educational intervention
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dust endotoxin load reduction
Number of subjects: 104
Study: 28651588

Group type: EXPERIMENTAL
Intervention: Health Information Technology (HIT) home monitoring
Number of subjects: 21
Study: 25226328

Group type: EXPERIMENTAL
Intervention: Massage treatment for 15 minutes by physiotherapist, consisting of light stroking, milking, friction, and skin rolling.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (EIMD-treated without massage).
Number of subjects: 21
Study: 23617607

Group type: EXPERIMENTAL
Intervention: Online Spaced Education (SE) programme
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no SE programme)
Number of subjects: 97
Study: 21570904

Group type: EXPERIMENTAL
Intervention: Isometric force task (torque rise time and force variability)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined measures across force and movement tasks (force variability and peak deceleration)
Number of subjects: 24
Study: 19926058

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual-dose sirolimus (8 mg cumulative loading dose, 2 mg/day for 7 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: High-dose sirolimus (24 mg cumulative loading dose, 2 mg/day for 7 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual-dose sirolimus
Number of subjects: 300

Group type: COMPARATOR
Intervention: High-dose sirolimus
Number of subjects: 300
Study: 17225518

Group type: EXPERIMENTAL
Intervention: Remifentanil combined with propofol anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl combined with propofol anesthesia
Number of subjects: 30
Study: 15513312

Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no isoflurane)
Number of subjects: 34
Study: 11811506

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) with bioabsorbable membrane
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (access flap alone)
Number of subjects: 112
Study: 9581180

Group type: EXPERIMENTAL
Intervention: Positioning support cushion
Number of subjects: 55

Group type: COMPARATOR
Intervention: No positioning support cushion
Number of subjects: 55
Study: 7974549

Group type: EXPERIMENTAL
Intervention: Video training for NIH Stroke Scale
Number of subjects: 162
Study: 2478778

Group type: EXPERIMENTAL
Intervention: Transdermally delivered nitroglycerin (NTG 10 mg/24 h)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1101755

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 50
Study: 29093005

Group type: EXPERIMENTAL
Intervention: CMV pp65-specific T cells with CMV-DC vaccination (CMV-ATCT-DC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline (CMV-ATCT-saline)
Number of subjects: 17
Study: 27058689

Group type: EXPERIMENTAL
Intervention: Holmium Laser Bladder Neck Incision (HoBNI)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional Bladder Neck Incision (C-BNI)
Number of subjects: 140
Study: 25636822

Group type: EXPERIMENTAL
Intervention: Policy-driven intervention to improve sun safety behaviour
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Volume of sunscreen utilized by Year 6 classes
Number of subjects: 20
Study: 23221623

Group type: EXPERIMENTAL
Intervention: Active anodal transcranial direct current stimulation (tDCS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study: 20439952

Group type: EXPERIMENTAL
Intervention: Chlorine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Moringa oleifera seeds
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Closed valved container
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study: 18192906

Group type: EXPERIMENTAL
Intervention: Ciclosporin A (CsA) dosage reduction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (stable CsA dose)
Number of subjects: 40
Study: 17171330

Group type: EXPERIMENTAL
Intervention: Collagen implant (CMI) with high tibial valgus osteotomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Correction only (valgization correction osteotomy)
Number of subjects: 60
Study: 12704306

Group type: EXPERIMENTAL
Intervention: Cervical manipulation and cervical extension-compression traction (vertical weight applied to the subject's forehead in the sitting position with a transverse load at the area of kyphosis)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 10748957

Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Silver Sulphadiazine
Number of subjects: 39
Study: 9364618

Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin (VP) 40 IU for three months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 1604262

Group type: EXPERIMENTAL
Intervention: Active PEMT collars
Number of subjects: 40

Group type: COMPARATOR
Intervention: Facsimile (placebo)
Number of subjects: 40
Study: 3890394

Group type: EXPERIMENTAL
Intervention: muzolimine (20 mg o.d.)
Number of subjects: 49

Group type: COMPARATOR
Intervention: acebutolol (400 mg o.d.)
Number of subjects: 49
Study: 29197947

Group type: EXPERIMENTAL
Intervention: Adapted dialectical behavior therapy (DBT) skills training for 10 sessions
Number of subjects: 31

Group type: COMPARATOR
Intervention: Waiting list comparison condition (control)
Number of subjects: 31
Study: 30439812

Group type: EXPERIMENTAL
Intervention: D + ASA (Duloxetine + Acetylsalicylic Acid 100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: E + placebo (Escitalopram + Placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance (measured by HAQ)
Number of subjects: 40
Study: 27029487

Group type: EXPERIMENTAL
Intervention: Deferiprone (20 mg/kg/day)
Number of subjects: 5
Study: 24908096

Group type: EXPERIMENTAL
Intervention: Lee Silverman voice treatment (16 sessions of 50-60 minutes over four weeks with extra home practice)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard speech and language therapy (dose determined by individual needs, not exceeding eight weeks of treatment)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard care with no speech and language therapy input for at least six months post-randomization)
Number of subjects: 60
Study: 23445512

Group type: EXPERIMENTAL
Intervention: Delayed sleep timing and increased sleepiness (ESS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combined subtypes of ADHD
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inattentive subtypes of ADHD
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Symptom-controlled participants
Number of subjects: 24
Study: 19769599

Group type: EXPERIMENTAL
Intervention: Low-dose aripiprazole adjunctive to antidepressant treatment (ADT)
Number of subjects: 186
Study: 20307427

Group type: EXPERIMENTAL
Intervention: Copper-oxide impregnated socks
Number of subjects: 56
Study: 16704570

Group type: EXPERIMENTAL
Intervention: Active TV viewing
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Passive TV exposure
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Viewing adult-targeted TV programs
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Adjusted odds ratios for passive TV exposure
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Adjusted odds ratios for viewing adult-targeted programs
Number of subjects: 321
Study: 12796831

Group type: EXPERIMENTAL
Intervention: Oral ondansetron 8 mg twice daily for seven days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45